First Tracks Biotherapeutics annual ebitda
2023
2024
First Tracks Biotherapeutics EBITDA Growth & History (TRAX)
First Tracks Biotherapeutics's calculated EBITDA was −$178.7M for fiscal 2024.
View full First Tracks Biotherapeutics company overviewFirst Tracks Biotherapeutics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | −$178.7M | −$62.6M | — |
| 2023 | 2023-12-31 | −$116.1M | — | — |
First Tracks Biotherapeutics quarterly ebitda
Q1.26
Q2.26
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | −$34.8M | $10.9M | — |
| Q1 2026 · Mar 31 | 2026-03-31 | −$52.7M | −$1.6M | — |
| Q2 2026 · Jun 30 | 2025-06-30 | −$45.8M | — | — |
| Q1 2026 · Mar 31 | 2025-03-31 | −$51.1M | — | — |
First Tracks Biotherapeutics ebitda trends
Between the periods ended 2023-12-31 and 2024-12-31, First Tracks Biotherapeutics's ebitda decreased from −$116.1M to −$178.7M, a change of −$62.6M. The latest reported quarter, Q2 2026 · Jun 30, shows −$34.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review First Tracks Biotherapeutics source filings ↗